DoubleLine ETF Adviser’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
DoubleLine ETF Adviser's REGN Position: Q3 2026 in Review
DoubleLine ETF Adviser sold out of Regeneron Pharmaceuticals (REGN) in Q3 2026, closing a stake of 1,209 shares — an estimated $754K sold.
DoubleLine ETF Adviser first reported a position in REGN in Q1 2026 and held it in 2 quarters. The position peaked at $1.02M in Q1 2026. 1,423 funds tracked by Wall St. Rank hold REGN as of Q3 2026.
- DoubleLine ETF Adviser reported no remaining Regeneron Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
- DoubleLine ETF Adviser sold 1,209 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $754K.
- DoubleLine ETF Adviser first reported a position in Regeneron Pharmaceuticals in Q1 2026 and held it in 2 quarters.
- DoubleLine ETF Adviser's Regeneron Pharmaceuticals position peaked at $1.02M in Q1 2026.
- 1,423 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.
Based on DoubleLine ETF Adviser's 13F filing for Q3 2026, filed 13 Nov 2026.